Virios therapeutics announces third quarter 2021 financial results and provides corporate update

Atlanta--(business wire)---- $viri #biotech--virios therapeutics, inc. (nasdaq: viri), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, reported today financial results for the third quarter ended september 30, 2021 and provided a corporate update at 8:30 a.m. est. “we are pleased to have enrolled over 200 patients into our landmark phase 2b fibromyalgia clinical trial, referred to as fortress, with the goal to
VIRI Ratings Summary
VIRI Quant Ranking